Pascal and Francis Bibliographic Databases

Help

Search results

Your search

kw.\*:("Ezetimibe")

Document Type [dt]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Language

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 406

  • Page / 17
Export

Selection :

  • and

À la découverte de l'ézétimibe = EzetimibeWATKINS, C.La Lettre du cardiologue. 2004, Num 378, pp 44-45, issn 0761-5035, 2 p.Article

Ezetimibe-Associated Immune ThrombocytopeniaPATTIS, Peter; WIEDERMANN, Christian J.The Annals of pharmacotherapy. 2008, Vol 42, Num 3, pp 430-433, issn 1060-0280, 4 p.Article

Simultaneous Liquid Chromatographic Determination of Ezetimibe and Simvastatin in Pharmaceutical ProductsRENATO OLIVEIRA, Paulo; BARTH, Thiago; TODESCHINI, Vitor et al.Journal of AOAC International. 2007, Vol 90, Num 6, pp 1566-1572, issn 1060-3271, 7 p.Article

Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemiaSALEN, G; VON BERGMANN, K; LÜTJOHANN, D et al.Circulation (New York, N.Y.). 2004, Vol 109, Num 8, pp 966-971, issn 0009-7322, 6 p.Article

Ezetimibe ameliorates cholecystosteatosisMATHUR, Abhishek; WALKER, Julia J; AL-AZZAWI, Hayder H et al.Surgery. 2007, Vol 142, Num 2, pp 228-233, issn 0039-6060, 6 p.Article

Ézétimibe : Le profil d'effets indésirables se précise = Ezetimibe adverse effectsLa Revue Prescrire. 2005, Vol 25, Num 261, issn 0247-7750, p. 350Article

Effectiveness of Ezetimibe in clinical practiceJURADO, Javier; SEIP, Richard; THOMPSON, Paul D et al.The American journal of cardiology. 2004, Vol 93, Num 5, pp 641-643, issn 0002-9149, 3 p.Article

Effectiveness of Thrice Weekly EzetimibeVENERO, Carmelo V; VENERO, Jose V; SEIP, Richard L et al.The American journal of cardiology. 2008, Vol 102, Num 9, pp 1205-1206, issn 0002-9149, 2 p.Article

Le médicament du mois Ezétimibe (Ezetrol®) = Ezetimibe (Ezetrol®)SCHEEN, A. J.RMLG. Revue médicale de Liège. 2004, Vol 59, Num 4, pp 246-250, issn 0370-629X, 5 p.Article

Concurrent determination of ezetimibe and its phase-I and II metabolites by HPLC with UV detection : Quantitative application to various in vitro metabolic stability studies and for qualitative estimation in bileSHAIK JAFAR SADIK BASHA; SHAIK ABDUL NAVEED; SRINIVAS, Nuggehally R et al.Journal of chromatography. B. 2007, Vol 853, Num 1-2, pp 88-96, issn 1570-0232, 9 p.Article

Effects of Mixed Micellar Lipids on Carotenoid Uptake by Human Intestinal Caco-2 CellsKOTAKE-NARA, Eiichi; NAGAO, Akihiko.Bioscience, biotechnology, and biochemistry. 2012, Vol 76, Num 5, pp 875-882, issn 0916-8451, 8 p.Article

Lack of clinically relevant drug-drug interactions when dalcetrapib is co-administered with ezetimibeDERKS, Michael; ABT, Markus; PHELAN, Mary et al.British journal of clinical pharmacology. 2010, Vol 70, Num 6, pp 825-833, issn 0306-5251, 9 p.Article

Données récentes sur l'EzetimibeCAZAUBON, M; AZAR, R.Angéiologie (Paris). 2010, Vol 62, Num 4, pp 42-43, issn 0003-3049, 2 p.Article

Ezetimibe Is an Inhibitor of Tumor AngiogenesisSOLOMON, Keith R; PELTON, Kristine; BOUCHER, Kelly et al.The American journal of pathology. 2009, Vol 174, Num 3, pp 1017-1026, issn 0002-9440, 10 p.Article

Diastereoselective reduction of 1-(4-fluorophenyl)-3(R)-[3-oxo-3-(4-fluorophenyl)-propyl]-4(S)-(4-hydroxyphenyl)azetidin-2-one to Ezetimibe by the whole cell catalyst Rhodococcus fascians MO22KYSLIKOVA, Eva; BABIAK, Peter; MARESOVA, Helena et al.Journal of molecular catalysis. B, Enzymatic. 2010, Vol 67, Num 3-4, pp 266-270, issn 1381-1177, 5 p.Article

In-vitro characterization of the six clustered variants of NPC1 L1 observed in cholesterol low absorbersYAMANASHI, Yoshihide; TAKADA, Tappei; SUZUKI, Hiroshi et al.Pharmacogenetics and genomics (Print). 2009, Vol 19, Num 11, pp 884-892, issn 1744-6872, 9 p.Article

Stress degradation studies on ezetimibe and development of a validated stability-indicating HPLC assaySINGH, Saranjit; SINGH, Baljinder; BAHUGUNA, Rakesh et al.Journal of pharmaceutical and biomedical analysis. 2006, Vol 41, Num 3, pp 1037-1040, issn 0731-7085, 4 p.Article

Structure of the major degradant of ezetimibeSANTA, Zsuzsanna; KOTI, Janos; SZOKE, Katalin et al.Journal of pharmaceutical and biomedical analysis. 2012, Vol 58, pp 125-129, issn 0731-7085, 5 p.Article

Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1OSWALD, Stefan; KÖNIG, Jörg; LÜTJOHANN, Dieter et al.Pharmacogenetics and genomics (Print). 2008, Vol 18, Num 7, pp 559-568, issn 1744-6872, 10 p.Article

L'ézétimibe (Ezetrol®) : le partenaire des statines = Ezetimibe (Ezetrol®): the statins' partnerDUCOBU, J; STERNON, J.Revue médicale de Bruxelles. 2004, Vol 25, Num 5, pp 456-461, issn 0035-3639, 6 p.Article

Cholesterol uptake and hepatitis C virus entryLUPBERGER, Joachim; FELMLEE, Daniel J; BAUMERT, Thomas F et al.Journal of hepatology. 2012, Vol 57, Num 1, pp 215-217, issn 0168-8278, 3 p.Article

What is the degradation product of ezetimibe?BARHATE, Chandrashekhar R; MOHANRAJ, Krishnapriya.Journal of pharmaceutical and biomedical analysis. 2011, Vol 55, Num 5, pp 1237-1238, issn 0731-7085, 2 p.Article

A LC-MS/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1OSWALD, Stefan; SCHEUCH, Eberhard; CASCORBI, Ingolf et al.Journal of chromatography. B. 2006, Vol 830, Num 1, pp 143-150, issn 1570-0232, 8 p.Article

Ezetimibe for management of hypercholesterolemiaMAURO, Vincent F; TUCKERMAN, Chad E.The Annals of pharmacotherapy. 2003, Vol 37, Num 6, pp 839-848, issn 1060-0280, 10 p.Article

Ezetimibe : A review of its metabolism, pharmacokinetics and drug interactionsKOSOGLOU, Teddy; STATKEVICH, Paul; JOHNSON-LEVONAS, Amy O et al.Clinical pharmacokinetics. 2005, Vol 44, Num 5, pp 467-494, issn 0312-5963, 28 p.Article

  • Page / 17